Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJID (1) BJMBR (1) Autor Costanzi-Strauss,E. (1) Estrela,Rita de Cássia E. (1) Fleury,Marcos K. (1) Gonçalves,José Carlos Saraiva (1) Kritski,Afrânio L. (1) Oliveira,Martha M. (1) Santos,Eliana Abreu (1) Silva,José Roberto Lapa e (1) Strauss,B.E. (1) Velasque,Luciane S. (1) Mais... Palavra-chave Adverse event (2) Clinical trial (1) Gene therapy (1) Hepatotoxicity (1) Induced liver injury from treatment of tuberculosis (1) Insertional mutagenesis (1) Polymorphisms of CYP2E1 and GST (1) Pulmonary tuberculosis (1) Retrovirus (1) Severe combined immune deficiency (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2019 (1) 2007 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Relationship of anti-tuberculosis drug-induced liver injury and genetic polymorphisms in CYP2E1 and GST BJID Santos,Eliana Abreu; Gonçalves,José Carlos Saraiva; Fleury,Marcos K.; Kritski,Afrânio L.; Oliveira,Martha M.; Velasque,Luciane S.; Silva,José Roberto Lapa e; Estrela,Rita de Cássia E.. ABSTRACT Setting: Treatment of tuberculosis (TB) can result in Drug-Induced Liver Injury (DILI) since hepatotoxic metabolites are formed during the biotransformation of isoniazid (INH).DILI can be related to the genetic profile of the patient. Single nucleotide polymorphisms in the CYP2E1 gene and GSTM1 and GSTT1 deletion polymorphisms have been associated with adverse events caused by INH. Objective: To characterize the genetic polymorphisms of CYP2E1, GSTT1 and GSTM1 in TB carriers. Design: This is an observational prospective cohort study of 45 patients undergoing treatment of TB. PCR-RFLP and multiplex-PCR were used. Results: The distribution of genotypic frequency in the promoter region (CYP2E1 gene) was: 98% wild genotype and 2% heterozygous.... Tipo: Info:eu-repo/semantics/article Palavras-chave: Adverse event; Polymorphisms of CYP2E1 and GST; Induced liver injury from treatment of tuberculosis; Hepatotoxicity; Pulmonary tuberculosis. Ano: 2019 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702019000600381 Combating oncogene activation associated with retrovirus-mediated gene therapy of X-linked severe combined immunodeficiency BJMBR Strauss,B.E.; Costanzi-Strauss,E.. A successful gene therapy clinical trial that also encountered serious adverse effects has sparked extensive study and debate about the future directions for retrovirus-mediated interventions. Treatment of X-linked severe combined immunodeficiency with an oncoretrovirus harboring a normal copy of the gc gene was applied in two clinical trials, essentially curing 13 of 16 infants, restoring a normal immune system without the need for additional immune-related therapies. Approximately 3 years after their gene therapy, tragically, 3 of these children, all from the same trial, developed leukemia as a result of this experimental treatment. The current understanding of the mechanism behind this leukemogenesis involves three critical and cooperating factors,... Tipo: Info:eu-repo/semantics/article Palavras-chave: Retrovirus; Insertional mutagenesis; Severe combined immune deficiency; Gene therapy; Adverse event; Clinical trial. Ano: 2007 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000500002 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco